This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FRLN Freeline Therapeutics (FRLN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Freeline Therapeutics Stock (NASDAQ:FRLN) Get Freeline Therapeutics alerts:Sign Up Key Stats Today's Range$6.48▼$6.4850-Day Range$6.43▼$6.4952-Week Range$2.11▼$8.74VolumeN/AAverage Volume12,055 shsMarket Capitalization$28.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. Read More Receive FRLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FRLN Stock News HeadlinesFreeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingApril 24, 2024 | globenewswire.comFreeline Therapeutics Stock (NASDAQ:FRLN) Dividends: History, Yield and DatesFebruary 25, 2024 | benzinga.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.July 6 at 1:00 AM | Porter & Company (Ad)Acquisition of Freeline by Syncona Becomes EffectiveFebruary 20, 2024 | finance.yahoo.comAcquisition of Freeline by Syncona Becomes EffectiveFebruary 20, 2024 | globenewswire.comFreeline Therapeutics Shareholders Approve Acquisition by SynconaFebruary 13, 2024 | finanznachrichten.deFreeline Shareholders Approve Acquisition by SynconaFebruary 12, 2024 | finance.yahoo.comFreeline Therapeutics Holdings plc (FRLN)February 9, 2024 | uk.finance.yahoo.comSee More Headlines FRLN Stock Analysis - Frequently Asked Questions How were Freeline Therapeutics' earnings last quarter? Freeline Therapeutics Holdings plc (NASDAQ:FRLN) released its earnings results on Tuesday, November, 9th. The company reported ($12.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($15.20) by $2.30. When did Freeline Therapeutics' stock split? Shares of Freeline Therapeutics reverse split on the morning of Friday, May 12th 2023.The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Freeline Therapeutics IPO? Freeline Therapeutics (FRLN) raised $150 million in an initial public offering on Friday, August 7th 2020. The company issued 8,823,529 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Freeline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Freeline Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Jabil (JBL), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings11/09/2021Today7/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:FRLN CIK1810031 Webwww.freeline.life Phone44-0-14-3890-6870FaxN/AEmployees152Year Founded2015Profitability EPS (Trailing Twelve Months)($5.5939) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-150.46% Return on Assets-97.01% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.07 per share Price / Book0.54Miscellaneous Outstanding Shares4,340,000Free Float4,259,000Market Cap$28.12 million OptionableNot Optionable Beta0.66 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:FRLN) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Tech forecaster George Gilder - who identified Amazon when it was still just an online bookstore and predicted...Eagle Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredElon’s New Currency (BUY NOW)Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...InvestorPlace | SponsoredMove your money (NOT into the next AI IPO)While headlines focus on AI IPOs, the world's largest investors are moving capital into one asset at the faste...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Freeline Therapeutics Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Freeline Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FRLN Stock Alerts